Esperion Therapeutics, which is focused on the treatment for elevated levels of low-density lipoprotein cholesterol, filed on Tuesday with the SEC to raise up to $70 million in an initial public offering. The Plymouth, MI-based company, which was founded in 1998 and failed to generate revenue in the 2012 fiscal year, plans to list on the NASDAQ under the symbol ESPR. Esperion Therapeutics initially filed confidentially on April 12, 2013. Credit Suisse and Citi are the joint bookrunners on the deal. No pricing terms were disclosed.
